Journal article
Romidepsin in peripheral and cutaneous T-cell lymphoma: Mechanistic implications from clinical and correlative data
SE Bates, R Eisch, A Ling, D Rosing, M Turner, S Pittaluga, HM Prince, MH Kirschbaum, SL Allen, J Zain, LJ Geskin, D Joske, L Popplewell, EW Cowen, ES Jaffe, J Nichols, S Kennedy, SM Steinberg, DJ Liewehr, LC Showe Show all
British Journal of Haematology | Published : 2015
DOI: 10.1111/bjh.13400
Abstract
Romidepsin is an epigenetic agent approved for the treatment of patients with cutaneous or peripheral T-cell lymphoma (CTCL and PTCL). Here we report data in all patients treated on the National Cancer Institute 1312 trial, demonstrating long-term disease control and the ability to retreat patients relapsing off-therapy. In all, 84 patients with CTCL and 47 with PTCL were enrolled. Responses occurred early, were clinically meaningful and of very long duration in some cases. Notably, patients with PTCL receiving romidepsin as third-line therapy or later had a comparable response rate (32%) of similar duration as the total population (38%). Eight patients had treatment breaks of 3·5 months to ..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
This work was supported by the intramural programme of the National Institutes of Health, USA, and by a CRADA with Celgene Corporation. The authors would also like to acknowledge individuals in the Cancer Therapy Evaluation Program (CTEP) for their participation in the sponsorship of this trial and the editorial assistance of Rob Robey.